Invokana Lawsuit Attorney
Amputations, Kidney Damage, Ketoacidosis, Flesh-eating Genital Infections
Invokana increases the risk of amputations of a toe, foot, or leg. It may also increase the risk of ketoacidosis (potential fatal kidney failure), and also cause a flesh-eating genital infection. On May 16, 2017, the U.S. FDA confirmed that a black-box warning must be included in the Invokana label. The revised label will state that Invokana raises the risk of people needing to have their legs or feet amputated.
Invokana Linked to Amputations
On May 18, 2016, the FDA first announced Invokana and Invokamet are linked to amputations. The agency had announced May 15, 2015 that it was investigating reports of some type 2 diabetes drugs – including Invokana and Invokamet – for causing a serious medical condition known as ketoacidosis.
Invokana Linked to Kidney Failure
According to the American Diabetes Association, ketoacidosis – also known as acidosis or diabetic ketoacidosis (DKA) – causes one to produce dangerous levels of blood acids, or keytones, which can lead to diabetic coma and can be fatal. The FDA is now reviewing the safety of all SGLT2 inhibitors to determine if the risk of ketoacidosis should be noted on the drugs’ labels, and also whether Invokana raises the risk of amputations.
Free Legal Consultation
Matthews & Associates is investigating potential Invokana lawsuits on behalf of anyone hospitalized due to ketoacidosis, diabetic ketoacidosis (DKA), ketosis, or acidosis while using Invokana or another Type 2 diabetes medication known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, and on behalf of anyone who may have lost a limb after taking Invokana.
If you were hospitalized with ketoacidosis while taking Invokana or a similar diabetes medication, or if you lost a limb or limbs after taking this drug, contact our legal staff today for a free legal case review regarding a potential lawsuit against the drug’s maker. By filing an Invokana lawsuit, you may be able to obtain compensation for medical bills, lost wages, pain and suffering, and other damages related to your injuries.
Diabetes Type 2 Medications
- Invokana (canagliflozin)
- Invokamet (canagliflozin/metformin)
- Jardiance (empagliflozin)
- Xigduo XR (dapagliflozin/metformin)
- Farxiga (dapagliflozin)
- Glyxambi (empagliflozin/linagliptin)
FDA Warning for Type 2 Diabetes Meds Invokana, Invokamet
FDA reviewed 20 adverse event reports from people seriously injured or hospitalized after taking type 2 diabetes drugs that included Invokana and Invokamet. These drugs belong to a class of medications known as sodium-glucose cotransporter-2 (SGLT2) inhibitors. They were approved by FDA to lower blood sugar levels in adults suffering from type 2 diabetes.
The FDA announcement warned patients to seek immediate medical help for symptoms of ketoacidosis. Symptoms include several potentially serious health issues:
- Difficulty breathing
- Abdominal pain
- Unusual fatigue or sleepiness
What is Invokana?
• A prescription drug made by Janssen Pharmaceuticals, a division of Johnson & Johnson.
• A drug meant to lower blood sugar in type 2 diabetic adults
• Not for people with type 1 diabetes
• Not for those with diabetic ketoacidosis (increased ketones)
• Not proven safe and effective for children under 18.
Invokana hit the market in May 2013 with a heavy and successful marketing campaign. Johnson & Johnson reported 2014 sales of Invokana totaling $569 million. Sales for 2015 total $266 million as of June 2015. Those are heavy sales for any drug, much less one as new as Invokana.
Invokana Legal Claim?
*To date, to our knowledge, no claims have been filed against the makers of Ivokana. We are only now investigating potential Invokana lawsuit claims.
Invokana Lawsuit Attorney
Working nationwide Matthews & Associates drug injury lawyers are ready to help those injured by ketoacidosis after taking diabetes medication such as Invokana, Invokamet, Jardiance and others. Please see our testimonials or call us for a free legal consultation regarding a potential Invokana lawsuit.